![]() |
市场调查报告书
商品编码
1472992
局部给药市场评估:依产品、给药途径、应用、最终用户、分销管道和地区划分的机会和预测(2017-2031)Topical Drug Delivery Market Assessment, By Product, By Route of Administration, By Application, By End-user, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F |
预计全球局部给药市场规模将从2023年的2,512亿美元成长到2031年的5,016.3亿美元,2024-2031年预测期间复合年增长率为9.03%。
研发活动的增加、癌症、传染病、糖尿病和呼吸道疾病发病率的上升以及对针头的恐惧日益增加正在支持市场的扩张。
全球局部给药市场的扩张是由于对无害且不需要医疗专业人员进行管理的便捷给药解决方案的需求不断增长所推动的。各种皮肤病盛行率的增加也是市场扩张的因素。烧伤发生率的增加增加了对有效管理和治疗烧伤的外用药物的需求。
目前正在进行各种研究活动,以使用微针贴片输送各种药物,以增强各种疾病和病症(例如类风湿性关节炎)的治疗功效。由于透过关节内注射局部给药是痛苦的,因此需要能够在发炎部位持续释放抗关节炎药物的微创给药解决方案。目前的研究重点是开发微针贴片,用于在豚鼠模型中微创和局部输送甲氨蝶呤。事实证明,与传统的皮下注射疗法或未经治疗的治疗相比,该贴片可确保药物持续释放,诱导最小的免疫反应,并显着减少关节中的类风湿标记和发炎。
研发活动的增加支持了局部给药市场的全球成长:
预计增加对各种研发活动的投资将在预测期内为市场提供有利的成长机会。人们越来越意识到本地药物输送系统提供的各种优势,包括易用性、自我给药、无痛药物输送和成本效益,从而推动了对研发活动的日益关注。
目前正在进行各种利用透皮给药系统治疗类风湿性关节炎的研究活动。使用透皮给药系统治疗类风湿性关节炎可以避免各种副作用并提高患者的依从性,使其成为有前途的选择。递送生物聚合物和小分子药物的透皮药物传递系统可望成为治疗类风湿性关节炎的有效手段。
增加烧伤:
由于各种环境、化学和电气因素导致的烧伤发生率不断增加,推动了全球局部给药市场的需求。根据世界卫生组织 (WHO) 估计,每年约有 18 万人死于烧伤。如此高的数字增加了对有效管理和治疗烧伤的外用药物的需求。借助外用抗生素可以将感染风险降至最低。这些药物也用于因合併症或伤口严重程度而面临败血症风险的患者。外用药物相对容易使用且可以无痛给药,这是它们优选用于治疗烧伤创面的主要原因。
该报告调查了全球本地药物输送市场,并提供市场定义和概述、市场规模趋势和预测、各个细分市场和地区的详细分析、行业结构、影响市场增长的因素分析以及案例研究。等
Global topical drug delivery market is projected to witness a CAGR of 9.03% during the forecast period 2024-2031F, growing from USD 251.2 billion in 2023 to USD 501.63 billion in 2031F. Increasing research and development activities, rising incidences of cancer, infectious diseases, diabetes, respiratory diseases, and growing needle phobia support the market expansion.
The increase in global topical drug delivery market size can be attributed to the rising demand for convenient drug delivery solutions that do not cause discomfort and require a medical professional for administration. The growing prevalence of different skin diseases can also be attributed to the market expansion. The increasing incidences of burn injuries are bolstering the requirement for topical drugs for the effective management and treatment of burns.
Various research activities are underway to deliver various drugs with the help of microneedle patches to ensure improved therapeutic efficacy for treating different diseases and disorders, such as rheumatoid arthritis. Due to the painful nature of the localized administration of the drugs via an intra-articular injection, drug delivery solutions that can ensure the sustained release of anti-arthritic drugs at the inflammation site in a minimally invasive manner are required. Research is being conducted that focuses on developing microneedle patches for minimally invasive and localized delivery of methotrexate in a guinea pig model. The patch was found to ensure the sustained release of the drug and elicit a minimal immune response and a distinct reduction in rheumatoid markers and inflammation at the joints compared to those treated through conventional hypodermic injections and remained untreated.
Rising Research and Development Activities Support the Global Topical Drug Delivery Market Growth
Rising investments in different research and development activities are expected to offer lucrative growth opportunities to the market over the forecast period. The increasing emphasis on research and development activities can be attributed to the rising awareness about the various benefits offered by topical drug delivery systems, such as ease of use, ability to be self-administered, painless delivery of medication, and cost-effectiveness.
Different research activities are underway to treat rheumatoid arthritis with transdermal drug delivery systems. Utilizing transdermal drug delivery systems for treating rheumatoid arthritis will help avoid various adverse effects, suboptimal bioavailability, and nonnegligible first-pass effects and enhance patient compliance, making them a promising option. The potential offered by transdermal drug delivery systems for delivering biomacromolecules and small-molecule drugs is expected to make them an effective means of treating rheumatoid arthritis.
Increasing Incidences of Burn Injuries
The increasing incidences of burn-related injuries due to various environmental, chemical, and electrical factors are boosting the global topical drug delivery market demand. As per the estimates of the World Health Organization (WHO), approximately 180,000 deaths are caused by burns every year. The high number of cases propels the need for topical drugs to manage and treat burns effectively. With the help of topical antimicrobial agents, the threat of infections is minimized. These drugs are also used by patients who are at risk from sepsis due to the associated comorbid factors or because of the severity of the wound. The relatively easy-to-use nature of topical drugs coupled with their painless administration are other significant factors because of which they are preferred for treating burn wounds.
North America is Expected to Witness Significant Market Expansion
Growing research and development activities, a well-established healthcare sector, and novel product launches by leading market players are supporting the expansion of the market. The increasing prevalence of various skin diseases in the region is another major factor bolstering the growth of the North American topical drug delivery market. According to the estimates of the American Cancer Society, approximately 100,640 new cases of melanoma will be diagnosed in the United States in 2024. About 41,470 cases are expected to be diagnosed in women and 59,170 in men.
Increasing spending on different research and development activities by various research institutions is another major factor bolstering the market growth in the region. For instance, the Medical University of South Carolina is conducting an interventional study to analyze the effects of the topical application of Aldara on patients with oral cancer. Aldara activates immune cells to eliminate and attack cancer cells and activates toll-like receptors in oral cancer cells, resulting in the self-destruction of tumor cells. The drug is currently approved by the Food and Drug Administration (FDA) for treating melanoma and skin cancer. The study is expected to conclude in March 2024.
Semi-solid Formulations Anticipated to Account for a Significant Global Topical Drug Delivery Market Share
The ease of use associated with semi-solid formulations such as creams, lotions, ointments, gels, and pastes is one of the major factors boosting segment growth. The stability offered by these products in atmospheric conditions as opposed to their solid and liquid counterparts, coupled with their high absorption properties, are propelling the requirement of semi-solid formulations. Increasing the provision of clearance by different regulatory bodies, such as the Food and Drug Administration (FDA), for various topical creams is another major factor supporting segment expansion. For instance, in 2023, Zydus Lifesciences Limited received approval from the Food and Drug Administration (FDA) to market and manufacture Metronidazole Topical Cream, 0.75 percent. Metronidazole is used to treat rosacea and is expected to aid in reducing swelling, redness, and pimples.
Home Care Settings Boost Global Topical Drug Delivery Market Demand
The growing popularity of home care settings can be attributed to the increasing awareness of the various associated advantages. These advantages include improved treatment outcomes and medical adherence, convenient nature compared to inpatient care, and different benefits for long-term therapy. The home healthcare industry in the United States is anticipated to add over 1 million new jobs between 2019 and 2029. The segment's expansion can also be attributed to the growth of the geriatric populace. According to the World Health Organization (WHO) estimate, between 2015 and 2050, the population over 60 will increase from 12% to 22%. Due to the hassle associated with outpatient treatment and hospitalization, various patients also prefer receiving treatment in home care settings for chronic or long-lasting conditions.
Future Market Scenario (2024-2031F)
According to the global topical drug delivery market analysis, the development of noninvasive and uncomplicated therapeutic strategies and target-oriented topical therapies is necessary in the future. Recent technological advancements in the delivery of drugs via the topical route have been transformed because of a deeper understanding of the permeation pathways through the skin and the molecular-level structure of the stratum corneum.
Various leading public research universities are conducting different studies. For instance, the University of Alabama at Birmingham is conducting a randomized, placebo-controlled, single-institution, double-blind phase IIB trial of topical DFMO and topical diclofenac in subjects who have a history of skin cancer. The participants of the study are 18 or older and have extensive actinic damage and a history of non-melanoma skin cancer. The participants of the study will be randomized to topical DFMO and topical diclofenac and placebo for the topical DFMO and placebo for the topical diclofenac once daily. The study is expected to conclude in December 2024.
Key Players Landscape and Outlook
Key participants in the topical drug delivery market support the growth by increasing research and development activities and raising investments to support such activities.
In 2023, Satio, a leading provider of technology solutions for therapeutics and diagnostics, was awarded a USD 3.5 million Small Business Innovation Research (SBIR) contract by the National Institute of Health's (NIH) Advanced Research Projects Agency for Health (ARPA-H). The contract is expected to support the development of SatioRx, an inexpensive and compact drug delivery device equipped with disposable microneedle components to ensure precise delivery of drugs. Under the contract, the company expects to leverage design features from its other patch-based devices. They also plan on utilizing feasibility data from their manually operated transdermal delivery devices. With these combination, Satio plans to develop a remotely controllable next-generation device.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.